person · Reporting owner

BLACKFORD GARY

Disclosed activity across 4 companies

Tapewire entity: 28335
SEC CIK: 0001156320

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ReShape Weightloss Inc.ETRM · Entity 137993	Director	February 08, 2017	February 10, 2017
Vyome Holdings, IncRSLS · Entity 1824	Director	July 22, 2021	September 17, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ReShape Weightloss Inc.

Report date February 08, 2017 · Filed February 10, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.12 · Expires 2027-02-08	Direct	30,000	Reported balance After 2017-02-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-08 · Grant · Acquired 30,000 · Balance 30,000 F2: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning the date shown.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.90 · Expires 2026-08-15	Direct	23	Reported balance Holding disclosure · report date 2017-02-08 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 23 F1: On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person, all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split. F2: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning the date shown.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance Holding disclosure · report date 2017-02-08 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: On December 27, 2016, EnteroMedics Inc. effected a 1-for-70 reverse stock split of its issued and outstanding shares of common stock, par value $0.01 per share, resulting in a proportional decrease in the total shares of common stock beneficially owned by the reporting person, all previously reported exercise prices, option grants and similar instruments convertible into common stock were proportionally adjusted to reflect the reverse split.

F2: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning the date shown.

Vyome Holdings, Inc

Report date July 22, 2021 · Filed September 17, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	Direct	253,429	Reported balance After 2021-07-22 transaction · row 1 1 source row Row 1 · 2021-07-22 · Grant · Acquired 253,429 · Balance 253,429 F1: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AVANOS MEDICAL, INC.

Report date July 27, 2026 · Filed July 28, 2026

Section 16 reporting ended · disclosed 2026-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectShares held in trust.	Reported balance After 2026-07-27 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2026-07-27 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. F2: These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-07-27 transaction · row 2 1 source row Row 2 · 2026-07-27 · Disposition to issuer · Disposed 79,590 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2026-07-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-27 · Disposition to issuer · Disposed 12,003 · Balance 0 F3: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F4: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.

F2: These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.

F3: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.

F4: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).

Wright Medical Group N.V.

Report date November 11, 2020 · Filed November 13, 2020

Section 16 reporting ended · disclosed 2020-11-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary Shares, par value EUR 0.03 per shareSEC Table I · non-derivative	Direct	Reported balance After 2020-11-11 transaction · row 1 1 source row Row 1 · 2020-11-11 · Other · Disposed 75,782 · Balance 0 F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 75,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.84 · Expires 2029-07-26	Direct	Reported balance After 2020-11-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-11 · Disposition to issuer · Disposed 11,691 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2028-07-24	Direct	Reported balance After 2020-11-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-11 · Disposition to issuer · Disposed 9,907 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.86 · Expires 2027-07-25	Direct	Reported balance After 2020-11-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-11 · Disposition to issuer · Disposed 10,275 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.24 · Expires 2026-07-19	Direct	Reported balance After 2020-11-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-11 · Disposition to issuer · Disposed 11,765 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.62 · Expires 2025-10-13	Direct	Reported balance After 2020-11-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-11 · Disposition to issuer · Disposed 11,018 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.06 · Expires 2024-05-13	Direct	Reported balance After 2020-11-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-11-11 · Disposition to issuer · Disposed 10,309 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.93 · Expires 2023-05-14	Direct	Reported balance After 2020-11-11 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-11-11 · Disposition to issuer · Disposed 10,309 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2022-05-09	Direct	Reported balance After 2020-11-11 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-11-11 · Disposition to issuer · Disposed 10,309 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.04 · Expires 2021-05-11	Direct	Reported balance After 2020-11-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-11-11 · Disposition to issuer · Disposed 7,731 · Balance 0 F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 75,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement).

F2: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 27, 2026 Filed Jul 28, 2026 21:35 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerRestricted Share Units · Derivative	12,003	$25.00	$300,075.00	Disclosure SEC source: 0001606498-26-000105 · wk-form4_1785274501.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,003 shares Expires not disclosed F3 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. F4 · price: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). F4 · derivative.expiration_date: Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings). Read SEC document
July 27, 2026 Filed Jul 28, 2026 21:35 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerCommon Stock	79,590	$25.00	$1,989,750.00	Disclosure SEC source: 0001606498-26-000105 · wk-form4_1785274501.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. Read SEC document
July 27, 2026 Filed Jul 28, 2026 21:35 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	Disposition to issuerCommon Stock	40,000	$25.00	$1,000,000.00	Disclosure SEC source: 0001606498-26-000105 · wk-form4_1785274501.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held in trust. Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement. F2 · shares: These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
May 08, 2026 Filed May 12, 2026 15:41 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantRestricted Share Units · Derivative	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-26-000079 · wk-form4_1778600497.xml · derivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,003 Underlying: Common Stock · 12,003 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025. F2 · derivative.exercise_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. F2 · derivative.expiration_date: The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors. Read SEC document
August 13, 2025 Filed Aug 15, 2025 16:02 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	PurchaseCommon Stock	40,000	$11.00	$439,800.00	Disclosure SEC source: 0001606498-25-000111 · wk-form4_1755273765.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held in trust. Disclosed balance after: 40,000 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.98 to $11.04, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These shares are held in trusts for the benefit of certain immediate family members of the Reporting Person. The Reporting Person is co-trustee of such trusts. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document
August 13, 2025 Filed Aug 15, 2025 16:02 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	PurchaseCommon Stock	20,000	$10.98	$219,500.00	Disclosure SEC source: 0001606498-25-000111 · wk-form4_1755273765.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,593 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.94 to $11.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 02, 2025 Filed Jan 6, 2025 18:53 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	12,003	$0.00	$0.00	Disclosure SEC source: 0001606498-25-000016 · wk-form4_1736189582.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,593 F1 · shares: Represents restricted share units issued to the Reporting Person on January 2, 2025 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
January 03, 2024 Filed Jan 4, 2024 20:10 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	8,378	$0.00	$0.00	Disclosure SEC source: 0001606498-24-000013 · wk-form4_1704399035.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,590 F1 · shares: Represents restricted share units issued to the Reporting Person on January 3, 2024 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
January 03, 2023 Filed Jan 5, 2023 14:59 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	7,008	$0.00	$0.00	Disclosure SEC source: 0001606498-23-000006 · wf-form4_167293074817193.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,212 F1 · shares: Represents restricted share units issued to the Reporting Person on January 3, 2023 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
January 03, 2022 Filed Jan 4, 2022 22:32 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,354	$0.00	$0.00	Disclosure SEC source: 0001606498-22-000007 · wf-form4_164133553326483.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,204 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2022 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
July 22, 2021 Filed Sep 17, 2021 22:25 UTC	Vyome Holdings, Inc RSLS · Entity 1824	GrantCommon Stock, $0.001 par value per share	253,429	$0.00	$0.00	Disclosure SEC source: 0001790300-21-000008 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,429 F1 · shares: These shares will vest and be issued with respect to 241,961 shares on each of July 22, 2021 and July 22, 2022 pursuant to a restricted stock unit granted under the ReShape Lifesciences Inc. Second Amended and Restated 2003 Stock Incentive Plan. Read SEC document
January 04, 2021 Filed Jan 6, 2021 14:12 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,005	$0.00	$0.00	Disclosure SEC source: 0001606498-21-000001 · wf-form4_160994233213479.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,850 F1 · shares: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	7,731	Not disclosed Strike: $15.04	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 10 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,731 shares Expires 2021-05-11 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	10,309	Not disclosed Strike: $20.75	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 9 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,309 shares Expires 2022-05-09 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	10,309	Not disclosed Strike: $23.93	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 8 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,309 shares Expires 2023-05-14 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	10,309	Not disclosed Strike: $29.06	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 7 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,309 shares Expires 2024-05-13 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	11,018	Not disclosed Strike: $20.62	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 6 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,018 shares Expires 2025-10-13 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	11,765	Not disclosed Strike: $21.24	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 5 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,765 shares Expires 2026-07-19 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	10,275	Not disclosed Strike: $27.86	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 4 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	9,907	Not disclosed Strike: $24.49	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Disposition to issuerStock Option (right to buy) · Derivative	11,691	Not disclosed Strike: $27.84	Not disclosed	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · derivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 F2 · price: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. F2 · derivative.exercise_date: Pursuant to the Purchase Agreement, each outstanding option to purchase Shares (a Wright Stock Option) that was outstanding immediately prior to the Acceptance Time was automatically canceled at the Acceptance Time and, at the Closing, exchanged for a cash payment equal to the product of (a) the number of Shares subject to the unexercised portion of such Wright Stock Option immediately prior to the Acceptance Time multiplied by (b) the excess, if any, of $30.75 over the applicable per Share exercise price of such Wright Stock Option, without interest and less applicable withholding taxes. Read SEC document
November 11, 2020 Filed Nov 13, 2020 20:03 UTC	Wright Medical Group N.V. WMGI · Entity 145358	OtherOrdinary Shares, par value EUR 0.03 per share	75,782	$30.75	$2,330,296.50	Disclosure SEC source: 0001235802-20-000124 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On November 4, 2019, Wright Medical Group N.V. (the Issuer) entered into a purchase agreement (the Purchase Agreement) with Stryker Corporation and its subsidiary, Stryker B.V. (the Purchaser). Pursuant to the terms of the Purchase Agreement, the Purchaser commenced a tender offer for all the outstanding ordinary shares, par value EUR 0.03 per share (Shares), of the Issuer (the Offer), and on November 11, 2020 (the Acceptance Time), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer, including 75,782 Shares tendered by the reporting person, in exchange for a cash payment equal to $30.75 per Share, without interest and less applicable withholding taxes (the Offer Consideration), which Offer Consideration will be paid as promptly as practicable following the Closing (as defined in the Purchase Agreement). Read SEC document
May 08, 2020 Filed May 11, 2020 22:09 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	PurchaseCommon Stock	5,000	$28.50	$142,500.00	Disclosure SEC source: 0001606498-20-000032 · wf-form4_158923482880589.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,845 F1 · shares: Represents issuers private purchase of stock units in the open market. Read SEC document
May 08, 2020 Filed May 11, 2020 22:09 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	PurchaseCommon Stock	5,000	$29.00	$145,000.00	Disclosure SEC source: 0001606498-20-000032 · wf-form4_158923482880589.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,845 F1 · shares: Represents issuers private purchase of stock units in the open market. Read SEC document
February 27, 2020 Filed Mar 2, 2020 21:14 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	5,154	$0.00 Strike: $17.82	$0.00	Disclosure SEC source: 0001235802-20-000009 · primary_doc.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,154 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised this option because the option was in the money and scheduled to expire on May 13, 2020. F3 · derivative.exercise_date: This option has fully vested. Read SEC document
February 27, 2020 Filed Mar 2, 2020 21:14 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	3,075	$30.22	$92,936.34	Disclosure SEC source: 0001235802-20-000009 · primary_doc.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,782 F1 · kind: The reporting person exercised this option because the option was in the money and scheduled to expire on May 13, 2020. F2 · balance_after: Includes 3,916 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
February 27, 2020 Filed Mar 2, 2020 21:14 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	5,154	$17.82	$91,844.28	Disclosure SEC source: 0001235802-20-000009 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised this option because the option was in the money and scheduled to expire on May 13, 2020. F2 · balance_after: Includes 3,916 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
January 02, 2020 Filed Jan 8, 2020 21:12 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,293	$0.00	$0.00	Disclosure SEC source: 0001606498-20-000003 · wf-form4_157851795782259.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,845 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2020 pursuant to the Avanos Medical, Inc. Outside Director's Compensation Plan. Read SEC document
July 26, 2019 Filed Jul 30, 2019 20:21 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	11,691	$0.00 Strike: $27.84	$0.00	Disclosure SEC source: 0001235802-19-000077 · primary_doc.xml · derivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,691 Underlying: Ordinary Shares · 11,691 shares Expires 2029-07-26 Read SEC document
July 26, 2019 Filed Jul 30, 2019 20:21 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,916	$0.00	$0.00	Disclosure SEC source: 0001235802-19-000077 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,703 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. F2 · balance_after: Includes 3,916 shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. Amended and Restated 2017 Equity and Incentive Plan. Read SEC document
March 07, 2019 Filed Mar 11, 2019 20:57 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionStock Option (right to buy) · Derivative	2,577	$0.00 Strike: $15.01	$0.00	Disclosure SEC source: 0001235802-19-000027 · primary_doc.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,577 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised this option because the option was in the money and scheduled to expire on May 13, 2019. F5 · derivative.exercise_date: This option has fully vested. Read SEC document
March 07, 2019 Filed Mar 11, 2019 20:57 UTC	Wright Medical Group N.V. WMGI · Entity 145358	SaleOrdinary Shares, par value EUR 0.03 per share	1,242	$31.57	$39,213.42	Disclosure SEC source: 0001235802-19-000027 · primary_doc.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,787 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.57 to $31.58, inclusive. The reporting person undertakes to provide to Wright Medical Group N.V., any security holder of Wright Medical Group N.V., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
March 07, 2019 Filed Mar 11, 2019 20:57 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Exercise / conversionOrdinary Shares, par value EUR 0.03 per share	2,577	$15.01	$38,680.77	Disclosure SEC source: 0001235802-19-000027 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person exercised this option because the option was in the money and scheduled to expire on May 13, 2019. F2 · balance_after: Total holdings were increased by one ordinary share due to a rounding error in the Form 4 report that was filed with the SEC on July 26, 2018. F3 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
January 02, 2019 Filed Jan 4, 2019 14:19 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,248	$0.00	$0.00	Disclosure SEC source: 0001606498-19-000004 · wf-form4_154661157495415.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,552 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2019, pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
July 25, 2018 Filed Jul 27, 2018 00:59 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	626	$24.83	$15,543.58	Disclosure SEC source: 0001235802-18-000114 · primary_doc.xml · nonDerivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,451 F3 · balance_after: Includes 3,804 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 24, 2018 Filed Jul 27, 2018 00:59 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	9,907	$0.00 Strike: $24.49	$0.00	Disclosure SEC source: 0001235802-18-000114 · primary_doc.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,907 Underlying: Ordinary Shares · 9,907 shares Expires 2028-07-24 F4 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 24, 2018. Read SEC document
July 24, 2018 Filed Jul 27, 2018 00:59 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,804	$0.00	$0.00	Disclosure SEC source: 0001235802-18-000114 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,077 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 7,390 ordinary shares that will be issued over time upon vesting pursuant to restricted stock units granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
May 03, 2018 Filed May 4, 2018 14:28 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	384	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000035 · wf-form4_152544406719197.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,304 F1 · shares: Represents restricted share units issued to the reporting person on May 3, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
January 02, 2018 Filed Jan 3, 2018 22:16 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	2,946	$0.00	$0.00	Disclosure SEC source: 0001606498-18-000012 · wf-form4_151501777566759.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,920 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2018 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:31 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantStock Option (right to buy) · Derivative	10,275	$0.00 Strike: $27.86	$0.00	Disclosure SEC source: 0001235802-17-000117 · primary_doc.xml · derivative · entry 2 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,275 Underlying: Ordinary Shares · 10,275 shares Expires 2027-07-25 F3 · derivative.exercise_date: This option vests in two annual installments, on the one-year and two-year anniversaries of July 25, 2017. Read SEC document
July 25, 2017 Filed Jul 26, 2017 20:31 UTC	Wright Medical Group N.V. WMGI · Entity 145358	GrantOrdinary Shares, par value EUR 0.03 per share	3,586	$0.00	$0.00	Disclosure SEC source: 0001235802-17-000117 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,273 F1 · shares: These ordinary shares will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. F2 · balance_after: Includes 3,586 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. 2017 Equity and Incentive Plan. Read SEC document
July 19, 2017 Filed Jul 21, 2017 20:08 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	1,428	$27.58	$39,384.24	Disclosure SEC source: 0001235802-17-000107 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,687 Read SEC document
February 08, 2017 Filed Feb 10, 2017 21:39 UTC	ReShape Weightloss Inc. ETRM · Entity 137993	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $7.12	$0.00	Disclosure SEC source: 0001209191-17-009562 · doc4.xml · derivative · entry 3 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-02-08 F2 · derivative.exercise_date: 25% of the shares subject to the option are exercisable immediately. The remaining 75% of the shares subject to the option shall vest in a series of thirty-six (36) successive equal monthly installments upon completion of each month beginning the date shown. Read SEC document
January 03, 2017 Filed Jan 5, 2017 15:08 UTC	AVANOS MEDICAL, INC. HYH · Entity 28189	GrantCommon Stock	3,749	$0.00	$0.00	Disclosure SEC source: 0001606036-17-000007 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,974 F1 · shares: Represents restricted share units issued to the reporting person on January 3, 2017 pursuant to the Halyard Health, Inc. Outside Director's Compensation Plan. Read SEC document
October 13, 2016 Filed Oct 17, 2016 20:25 UTC	Wright Medical Group N.V. WMGI · Entity 145358	Tax withholdingOrdinary Shares, par value EUR 0.03 per share	1,177	$23.71	$27,906.67	Disclosure SEC source: 0001686266-16-000002 · primary_doc.xml · nonDerivative · entry 1 BLACKFORD GARY · CIK 0001156320 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,115 F1 · balance_after: Includes 4,094 ordinary shares that will be issued over time upon vesting pursuant to a restricted stock unit granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.